Professor Ramesh Chandra has made sustained, outstanding contributions to the invention, discoveryand development ofnew drugs. He has discoverednovel molecules such as EM011, EM012, EM015, (which are based on natural opioid, noscapine), which display unique anti-microtubule properties (high efficacy and no detectable toxicity towards tissues). In particular he has demonstrated high promise of EM011 (bromo-noscapine) in leukemia treatment, and of EM015 (chloro-noscapine) in breast tumor regression, in comparative studies with other anti-microtubule acting drugs. He has projected a therapy for neonatal jaundice, which has gained in-depth investigations on binding affinity of Heme Oxygenase Inhibitor, Sn-protoporphyrin and Sn-mesoporphyrin, with proteins, apomyoglobin and human serum albumin and mechanism of interaction of retinoic acid with Heme Oxygenase and other heme metabolic enzymes.

Prof Chandra has shown that heterocyclic compounds such as 5-(4-methylpiperazin-1-yl)-2-[2’-(3,4-dimethoxyphenyl)-5’-benzimidazolyl]-benzimidazole (DMA) and 5-(4-methyl-piperazin-1-yl)-2-[2’{2”-(4-hydorxy-3-methoxyphenyl)-5”-benzimidazolyl}-5’-benz-imidazolyl}benzimidazole (TBZ) are good novel ligands which provide increase sequence and structure selective recognition and enhanced fluorescence upon DNA minor groove binding; the features have special significance for development as probes for chromatin structure stability.

Also, Prof Chandra has developed several polymer based non-viral vectors and successfully demonstrated their efficacy to deliver genes and siRNA to mammalian cells by exploring chitosan and PEI & modulate them to fabricate nanoparticles for delivery of genes and siRNA.